In the current study, we offer an alternative strategy that may improve the effectiveness of cilengitide for GBM, given that our preclinical trials demonstrated that dual targeting of integrin αv (using cilengitide) and STAT3 (using WP1066) generates a potent antitumor effect in GBM mouse models. The gene discussed is STAT3; the disease is glioblastoma.